Puma Biotechnology Inc (PBYI)
5.02
+0.14
(+2.87%)
USD |
NASDAQ |
Apr 26, 16:00
5.03
+0.01
(+0.20%)
After-Hours: 20:00
Puma Biotechnology Enterprise Value: 245.72M for April 26, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 26, 2024 | 245.72M |
| April 25, 2024 | 238.97M |
| April 24, 2024 | 236.56M |
| April 23, 2024 | 251.02M |
| April 22, 2024 | 252.95M |
| April 19, 2024 | 245.24M |
| April 18, 2024 | 244.27M |
| April 17, 2024 | 252.95M |
| April 16, 2024 | 249.57M |
| April 15, 2024 | 261.63M |
| April 12, 2024 | 257.77M |
| April 11, 2024 | 268.37M |
| April 10, 2024 | 270.06M |
| April 09, 2024 | 284.76M |
| April 08, 2024 | 275.12M |
| April 05, 2024 | 276.57M |
| April 04, 2024 | 269.34M |
| April 03, 2024 | 261.63M |
| April 02, 2024 | 258.25M |
| April 01, 2024 | 258.25M |
| March 28, 2024 | 259.22M |
| March 27, 2024 | 272.71M |
| March 26, 2024 | 273.68M |
| March 25, 2024 | 273.20M |
| March 22, 2024 | 260.66M |
| Date | Value |
|---|---|
| March 21, 2024 | 261.63M |
| March 20, 2024 | 230.05M |
| March 19, 2024 | 211.01M |
| March 18, 2024 | 228.36M |
| March 15, 2024 | 244.75M |
| March 14, 2024 | 255.36M |
| March 13, 2024 | 260.66M |
| March 12, 2024 | 261.63M |
| March 11, 2024 | 268.37M |
| March 08, 2024 | 261.63M |
| March 07, 2024 | 280.91M |
| March 06, 2024 | 270.30M |
| March 05, 2024 | 253.43M |
| March 04, 2024 | 262.11M |
| March 01, 2024 | 287.66M |
| February 29, 2024 | 303.57M |
| February 28, 2024 | 321.88M |
| February 27, 2024 | 315.14M |
| February 26, 2024 | 316.10M |
| February 23, 2024 | 315.80M |
| February 22, 2024 | 285.31M |
| February 21, 2024 | 313.90M |
| February 20, 2024 | 327.24M |
| February 16, 2024 | 342.49M |
| February 15, 2024 | 336.77M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
97.23M
Minimum
May 11 2022
1.269B
Maximum
May 02 2019
287.58M
Average
263.41M
Median
Oct 13 2021
Enterprise Value Benchmarks
| ADMA Biologics Inc | 1.574B |
| Pfizer Inc | 201.86B |
| Sarepta Therapeutics Inc | 11.65B |
| Immunogen Inc (DELISTED) | -- |
| Regeneron Pharmaceuticals Inc | 88.08B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 12.27M |
| Revenue (Quarterly) | 72.18M |
| Total Expenses (Quarterly) | 57.38M |
| EPS Diluted (Quarterly) | 0.25 |
| Gross Profit Margin (Quarterly) | 66.30% |
| Profit Margin (Quarterly) | 17.00% |
| Earnings Yield | 8.96% |
| Operating Earnings Yield | 13.94% |
| Normalized Earnings Yield | 9.215 |